ArticleNature communications2025
Building lactams by highly selective hydrodeoxygenation of cyclic imides using an alumina-supported AgRe bimetallic nanocatalyst.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Controlling Selectivity at the First Hydrogenation Level: Synthesis of 3-Hydroxyisoindolines by Heterogeneously Silver-Catalyzed Monohydrogenation of Phthalimides.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Synthesis of Azaisoindolinones by Heterogeneous Catalyzed Regioselective Hydrodeoxygenation ofACS sustainable chemistry & engineering · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The rational design of robust nanocatalysts containing the suitable active sites for building relevant organic compounds, such as lactams, is a desired approximation towards the development of a sustainable fine chemistry field. In that sense, the design of a proper nanomaterial able to mediate the selective hydrodeoxygenation of cyclic imides to lactams with high tolerance to the preservation of aromatic rings remains rather unexplored. Here, we show the design of a bimetallic AgRe nanomaterial with notable activity and selectivity to mediate this transformation affording more than 60 lactams from the corresponding imides. Interestingly, in this work we disclose that the optimal AgRe nanocatalyst is constituted by AgReO
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.